“…It has been shown that the intact tandem CARDs are essential and sufficient for signaling [9,36,37], and mammalian RIG-I mutants with a CARD deletion or CARD point mutations (T55I or S183I) all function as a dominant inhibitor in its signaling [9,11,38]. It has also been revealed in mammals that the RIG-I downstream signaling via MAVS requires the recruitment of TRIM25 and other ubiquitination enzymes to synthesize unanchored K63-linked polyubiquitin chains binding to the CARD domains [36,37,39,40]. In the present study, RIG-Ia, the insertion variant of RIG-I with additional 38-aa residues in the CARD2 domain had no direct role in the activation of type I IFN promoter or antiviral defense, although the expression level of RIG-Ia could be induced under E. tarda or SVCV infections.…”